ReviewFEBS letters2016
Inherited heart disease - what can we expect from the second decade of human iPS cell research?
Review in FEBS letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.Pharmacological reports : PR · 2020Pooled it
- Review
- Utilizing human induced pluripotent stem cells to study atrial arrhythmias in the short QT syndrome.Journal of molecular and cellular cardiology · 2023Article
- Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.Journal of the American Heart Association · 2021Article
- Current strategies of mechanical stimulation for maturation of cardiac microtissues.Biophysical reviews · 2021Review
- Article
- Inherited cardiac diseases, pluripotent stem cells, and genome editing combined-the past, present, and future.Stem cells (Dayton, Ohio) · 2020Review
- Feasibility of Using Adjunctive Optogenetic Technologies in Cardiomyocyte Phenotyping - from the Single Cell to the Whole Heart.Current pharmaceutical biotechnology · 2020Review
- Review
- Pluripotent Stem Cell-Derived Cardiomyocyte Transplantation for Heart Disease Treatment.Current cardiology reports · 2019Review
- 3D Cardiac Cell Culture: A Critical Review of Current Technologies and Applications.Frontiers in cardiovascular medicine · 2019Review
- Diagnosing rare diseases after the exome.Cold Spring Harbor molecular case studies · 2018Review
- Ectopic hTERT expression facilitates reprograming of fibroblasts derived from patients with Werner syndrome as a WS cellular model.Cell death & disease · 2018Article
- Human Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets Expressing Genetically Encoded Voltage Indicator for Pharmacological and Arrhythmia Studies.Stem cell reports · 2018Article
- Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes.Cellular and molecular life sciences : CMLS · 2017Review
- Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies.Disease models & mechanisms · 2017Review
- Turning Potential Into Action: Using Pluripotent Stem Cells to Understand Heart Development and Function in Health and Disease.Stem cells translational medicine · 2017Article
- Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs).Journal of visualized experiments : JoVE · 2017Article
- Perspectives and Challenges of Pluripotent Stem Cells in Cardiac Arrhythmia Research.Current cardiology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Induced pluripotent stem cells (iPSCs) were first generated 10 years ago. Their ability to differentiate into any somatic cell type of the body including cardiomyocytes has already made them a valuable resource for modelling cardiac disease and drug screening. Initially human iPSCs were used mostly to model known disease phenotypes; more recently, and despite a number of recognised shortcomings, they have proven valuable in providing fundamental insights into the mechanisms of inherited heart disease with unknown genetic cause using surprisingly small cohorts. In this review, we summarise the progress made with human iPSCs as cardiac disease models with special focus on the latest mechanistic insights and related challenges. Furthermore, we suggest emerging solutions that will likely move the field forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.